INS and metabolic disease: Brain glucose metabolism is impaired in AD, and growing evidence supports the concept that AD is fundamentally a metabolic disease with progressive dysfunction in brain glucose utilization and responsiveness to insulin and insulin-like growth factor stimulation (Freude et al., 2009; Schuh et al., 2011).